×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Press Release

View printer-friendly version
Amgen's Third Quarter 2009 Adjusted Earnings Per Share Increased 21 Percent to $1.49
Third Quarter 2009 Revenue Decreased 2 Percent to $3.8 Billion

THOUSAND OAKS, Calif., Oct. 21 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) reported adjusted earnings per share (EPS) of $1.49 for the third quarter of 2009, an increase of 21 percent compared to $1.23 for the third quarter of 2008. Adjusted net income increased 16 percent to $1,518 million in the third quarter of 2009 compared to $1,308 million in the third quarter of 2008.

Total revenue decreased 2 percent during the third quarter of 2009 to $3,812 million versus $3,875 million in the third quarter of 2008.

"Our third quarter results reflect the continued stability of our core businesses in the face of increased competition," said Kevin Sharer, chairman & chief executive officer. "We are pleased by the results of clinical studies for denosumab and Vectibix that we recently presented at a scientific meeting, and look forward to making these innovative medicines available to patients in their respective indications."

Adjusted EPS and adjusted net income for the third quarter of 2009 and 2008 exclude, for the applicable periods, stock option expense, certain expenses related to acquisitions, a strategic decision to change manufacturing processes and the resolution of certain non-routine transfer pricing issues with the Internal Revenue Service (IRS), and certain other items. In addition, adjusted EPS and adjusted net income for the third quarter of 2009 and 2008 exclude the incremental non-cash interest expense resulting from a change in accounting for convertible debt as discussed below. These expenses and other items are itemized on the attached reconciliation tables.

On a reported basis and calculated in accordance with United States (U.S.) Generally Accepted Accounting Principles (GAAP), Amgen's GAAP EPS were $1.36 in the third quarter of 2009, a 30 percent increase compared to $1.05 in the same quarter last year. GAAP net income increased 24 percent to $1,386 million in the third quarter of 2009 from $1,121 million in the third quarter of 2008. GAAP net income for the third quarter of 2008 was negatively impacted by an $84 million inventory write-off resulting from a strategic decision to change manufacturing processes. Effective Jan. 1, 2009, Amgen adopted a new accounting standard which changed the method of accounting for the Company's convertible notes. In addition, as required, the Company also revised its previously reported financial statements to apply this change in accounting to prior periods. Under this new accounting method, the Company's GAAP EPS and net income have been reduced as a result of recognizing incremental non-cash interest expense. In connection with adopting this new accounting standard, Amgen recorded $63 million and $59 million of additional non-cash interest expense in the third quarter of 2009 and 2008, respectively. In addition, the Company's previously reported GAAP EPS and net income for the third quarter of 2008 have been reduced by $0.04 per share and $37 million to $1.05 per share and $1,121 million, respectively, as a result of adopting this new accounting method.

Product Sales Performance

During the third quarter of 2009, total product sales decreased 1 percent to $3,736 million from $3,784 million in the third quarter of 2008. Sales in the U.S. totaled $2,918 million in the third quarter of 2009, relatively unchanged versus $2,929 million in the third quarter of 2008. International sales decreased 4 percent to $818 million versus $855 million for the third quarter of 2008. The decline in third quarter 2009 international sales reflects the unfavorable impact of changes in foreign exchange, which were in aggregate approximately $76 million. Excluding the impact of foreign exchange, total product sales increased 1 percent and international product sales increased 5 percent.

Worldwide sales of Aranesp(®) (darbepoetin alfa) decreased 19 percent to $685 million in the third quarter of 2009 versus $845 million during the third quarter of 2008. In the U.S., Aranesp sales decreased 27 percent to $333 million in the third quarter of 2009 versus $458 million in the third quarter of 2008. U.S. sales of Aranesp in the third quarter of 2008 were positively impacted by $54 million due to a change in the accounting estimate related to product sales return reserves. Excluding the positive impact of this prior year change in the accounting estimate, U.S. sales of Aranesp decreased 18 percent in the third quarter of 2009 versus the prior year. The decrease was driven by a decline in demand reflecting the negative impact, primarily in the supportive cancer care setting, of additional product label changes which occurred in August 2008, and a decrease in average net sales price. In addition, the decrease in sales also reflects, to a lesser degree, a slight loss of segment share. International Aranesp sales decreased 9 percent to $352 million in the third quarter of 2009 versus $387 million in the third quarter of 2008 due to the unfavorable impact of changes in foreign exchange, which were in aggregate approximately $29 million and, to a lesser extent, segment decline. Excluding the impact of foreign exchange, international Aranesp product sales decreased 2 percent. Excluding the impact of the change in the accounting estimate related to product sales return reserves and foreign exchange, worldwide product sales decreased 10 percent in the third quarter of 2009 versus the prior year.

Sales of EPOGEN(®) (Epoetin alfa) increased 5 percent to $663 million in the third quarter of 2009 versus $634 million in the third quarter of 2008 due to an increase in demand. The increase in demand is principally due to patient population growth and, to a lesser extent, increases in average net sales price and dose/utilization.

Combined worldwide sales of Neulasta(®) (pegfilgrastim) and NEUPOGEN(®) (Filgrastim) increased 2 percent to $1,210 million in the third quarter of 2009 versus $1,192 million for the third quarter of 2008. Combined sales of Neulasta and NEUPOGEN in the U.S. were $897 million in the third quarter of 2009 versus $856 million in the third quarter of 2008, an increase of 5 percent due primarily to an increase in demand. The increase in demand was driven by an increase in units sold and an increase in average net sales price. Combined international sales decreased 7 percent to $313 million in the third quarter of 2009 versus $336 million for the third quarter of 2008. This decline is due to the unfavorable impact of changes in foreign exchange, which were in aggregate approximately $33 million, partially offset by an increase in demand driven by segment growth and by the continued conversion from NEUPOGEN to Neulasta. Excluding the impact of foreign exchange, combined worldwide product sales of Neulasta and NEUPOGEN increased 4 percent and international product sales increased 3 percent.

Sales of Enbrel(®) (etanercept) increased 3 percent in the third quarter of 2009 to $924 million versus $893 million in the third quarter of 2008, driven primarily by an increase in demand, partially offset by a favorable change in the accounting estimate recorded in the third quarter 2008 related to accruals for sale incentives. The increase in demand was principally due to a high single digit increase in the average net sales price partially offset by a decrease in units sold due to share declines as a result of increased competitive activity in dermatology. ENBREL continues to maintain a leading position in both the rheumatology and dermatology segments.

Worldwide sales of Sensipar(®) (cinacalcet) increased 2 percent to $165 million in the third quarter of 2009 versus $161 million during the third quarter of 2008, primarily as a result of increased international demand. U.S. sales declined 3 percent driven by a decrease in units sold.

Vectibix(®) (panitumumab) sales for the third quarter of 2009 were $58 million as compared to $41 million in the third quarter of 2008. Sales growth for the third quarter was driven by international demand as a result of recent launches of Vectibix in Europe. U.S. sales declined 12 percent driven by a decrease in units sold.

Operating Expense Analysis on an Adjusted Basis:

Cost of sales decreased 8 percent to $542 million in the third quarter of 2009 versus $590 million in the third quarter of 2008 primarily driven by lower royalty expenses, lower excess inventory write-offs, and lower excess capacity charges partially offset by higher fill and finish costs resulting from lower utilization at our manufacturing facility in Puerto Rico.

Research & Development (R&D) expenses decreased 12 percent to $613 million in the third quarter of 2009 versus $700 million in the third quarter of 2008. This decrease was primarily driven by lower clinical trial costs and lower staff-related expenses, due in part to the optimization of our clinical supply network.

Selling, General & Administrative (SG&A) expenses increased 3 percent to $913 million in the third quarter of 2009 versus $890 million in the third quarter of 2008. This increase was due to increased spending for activities in anticipation of the approval and launch of Prolia(TM) (denosumab), higher promotional expenses for marketed products, and higher expenses associated with the Pfizer (formerly Wyeth) profit share due to higher ENBREL sales partially offset by lower litigation expenses, lower staff related expenses, and expense recoveries associated with the GlaxoSmithKline collaboration agreement for Prolia in postmenopausal osteoporosis (PMO) in Europe, Australia, New Zealand, and Mexico.

Excluding expenses associated with the Pfizer profit share of $306 million and $298 million in the third quarter of 2009 and 2008, respectively, adjusted SG&A expenses in the third quarter of 2009 increased 3 percent versus the same quarter last year.

The adjusted tax rate in the third quarter of 2009 was 12.9 percent compared to 22.7 percent in the third quarter of 2008. The decrease in the adjusted tax rate is primarily due to the favorable impact of settling IRS and California tax audits for prior years, the impact of which is specific to the third quarter. In addition, the adjusted tax rate is lower due to an increase in bulk manufacturing and profits in Puerto Rico and the fact that the Federal R&D tax credit had not been extended in the third quarter of 2008. The third quarter adjusted tax rate is not indicative of the anticipated full year rate, which is expected to be approximately 18 percent.

Average diluted shares for adjusted EPS in the third quarter of 2009 were 1,021 million versus 1,063 million in the third quarter of 2008.

Capital expenditures for the third quarter of 2009 were approximately $130 million versus $159 million in the third quarter of 2008. Worldwide cash and marketable securities were $14.0 billion and adjusted outstanding debt was $12.2 billion at the end of the third quarter of 2009. The Company's adjusted outstanding debt excludes the impact of adopting a new accounting standard on the carrying values of its convertible debt. The Company's outstanding debt presented in accordance with GAAP was $11.5 billion at the end of the third quarter of 2009.

2009 Guidance Update

The Company reaffirmed that revenues for 2009 are trending towards the upper end of the current guidance range of $14.4 to $14.8 billion. Amgen now expects 2009 adjusted EPS to be in the range of $4.90 to $5.05, an increase from the previous range of $4.80 to $4.95, excluding stock option expense, certain expenses related to acquisitions, the income tax benefit, net as a result of resolving certain non-routine transfer pricing issues with the IRS, the incremental non-cash interest expense resulting from the change in accounting for convertible debt, and certain other items itemized on the reconciliation table below.

The Company still expects 2009 capital expenditures to be less than $600 million.

Third Quarter Product and Pipeline Update

The Company provided updates on selected products and clinical programs.

Prolia: The Company reviewed the Complete Response Letter that the U.S. Food and Drug Administration (FDA) has issued for the Biologic License Applications (BLA) for Prolia in the treatment and prevention of PMO. The Complete Response Letter on the Prolia PMO applications requested several items, including further information on the design and background adverse event rates that will inform the methodology of Amgen's previously submitted post-marketing surveillance program. This letter does not require additional pre-marketing clinical trials to complete the review of the PMO treatment indication. The FDA has requested a new clinical program to support approval of Prolia for the prevention of PMO indication. The FDA has determined that a Risk Evaluation and Mitigation Strategy (REMS) is necessary for Prolia and must include a medication guide, a communication plan, and a timetable for submission of assessments of the REMS. The FDA acknowledged receipt of Amgen's previously submitted proposed REMS materials. The FDA has also requested all updated safety data related to Prolia.

The Company also announced that it has received a Complete Response Letter issued by the FDA for the BLA for Prolia in the treatment and prevention of bone loss due to hormone ablation therapy (HALT) in breast and prostate cancer patients. The Complete Response Letter on the Prolia HALT applications requested additional information regarding the safety of Prolia in patients with breast cancer receiving aromatase inhibitor therapy and patients with prostate cancer receiving androgen deprivation therapy. Specifically, the FDA has requested results from additional adequate and well-controlled clinical trials demonstrating that Prolia has no detrimental effects on either time-to-disease progression or overall survival.

Amgen is reviewing both Complete Response Letters and will work with the FDA to determine the appropriate next steps regarding these applications.

The Company announced it expects that data from a study of the effect of denosumab on skeletal-related events in patients with bone metastases from prostate cancer will be available in the first quarter of 2010. The Company also announced that it will include results from all three of its skeletal-related events studies (breast, solid tumors or multiple myeloma, and prostate cancer) in its regulatory filings for marketing approval in the oncology setting next year.

Aranesp: The Company discussed the large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp(®) Therapy, or TREAT). Treatment of anemia with Aranesp to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment. The two primary endpoints were a composite of time to all-cause mortality or cardiovascular morbidity (including heart failure, heart attack, stroke, or hospitalization for myocardial ischemia) and a composite of time to all-cause mortality or chronic renal replacement therapy. Among the components of the TREAT outcomes measures, stroke, which has been noted in the Aranesp label since 2001, was more likely to occur in the patients who received Aranesp (101 patients [5.0 percent] vs. 53 patients [2.6 percent]; hazard ratio, 1.92; 95 percent CI, 1.38 to 2.68; P<0.001). Further, among patients with a history of cancer at baseline, there were 60 deaths from any cause in the 188 patients assigned to Aranesp and 37 deaths in the 160 patients assigned to placebo (P=0.13 by the log-rank test). In this subgroup, 14 of the 188 patients assigned to Aranesp died from cancer, as compared with 1 of the 160 patients assigned to placebo (P=0.002 by the log-rank test). Aranesp treatment was associated with a statistically significant reduction in blood transfusions. Additional data will be published soon and presented at the American Society of Nephrology Renal Week on October 30th and the American Heart Association scientific sessions in November.

Non-GAAP Financial Measures

Management has presented its operating results in accordance with GAAP and on an "adjusted" (or non-GAAP basis) for the three and nine months ended Sept. 30, 2009 and 2008. In addition, management has presented its outstanding debt in accordance with GAAP and on an "adjusted" (or non-GAAP basis) on Sept. 30, 2009. The Company believes that the presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. The Company uses these non-GAAP financial measures in connection with its own budgeting and financial planning. These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in conformity with GAAP.

Forward-Looking Statements

This news release contains forward-looking statements that involve significant risks and uncertainties, including those discussed below and others that can be found in our Form 10-K for the year ended Dec. 31, 2008, and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may differ materially from those we project. The Company's results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments (domestic or foreign) involving current and future products, sales growth of recently launched products, competition from other products (domestic or foreign) and difficulties or delays in manufacturing our products. In addition, sales of our products are affected by reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers.

About Amgen

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives. To learn more about our pioneering science and our vital medicines, visit www.amgen.com.

    Amgen Inc.
    Condensed Consolidated Statements of Income and
    Reconciliation of GAAP Earnings to "Adjusted" Earnings
    (In millions, except per share data)
    (Unaudited)


                       Three Months Ended         Three Months Ended
                       September 30, 2009         September 30, 2008
                       ------------------        ---------------------
                          Adjust-                        Adjust-
                   GAAP    ments   "Adjusted"   GAAP (a)  ments  "Adjusted"
                   ----   -------   --------   --------  -------  --------
    Revenues:
      Product
       sales      $3,736    $-       $3,736     $3,784     $-      $3,784
      Other
       revenues       76     -           76         91      -          91
                     ---   ---          ---        ---    ---         ---
        Total
         revenues  3,812     -        3,812      3,875      -       3,875
                   -----   ---        -----      -----    ---       -----


      Cost of sales
       (excludes
       amortization
       of certain
       acquired
       intangible
       assets
       presented
       below)        545    (3) (b)     542        677     (3) (b)    590
                                                          (84) (h)
      Research and
       development   647   (13) (b)     613        729    (12) (b)    700
                            (3) (c)                       (17) (d)
                           (18) (d)
      Selling,
       general
       and
       adminis-
       trative       932   (13) (b)     913        900    (10) (b)    890
                            (6) (c)
      Amortization
       of certain
       acquired
       intangible
       assets         74   (74) (e)       -         74    (74) (e)      -
      Other
       charges         9    (1) (c)       -         12     (8) (c)      -
                            (8) (f)                        (4) (f)
                     ---   ---          ---        ---    ---         ---
        Total
         operating
         expenses  2,207  (139)       2,068      2,392   (212)      2,180
                   -----  ----        -----      -----   ----       -----

    Operating
     income        1,605   139        1,744      1,483    212       1,695

      Interest
       expense,
       net           139   (63) (g)      76        133    (59) (g)     74
      Interest
       and
       other
       income,
       net            74                 74         62      9  (c)     71
                     ---                ---        ---    ---         ---

    Income
     before
     income
     taxes         1,540   202        1,742      1,412    280       1,692

    Provision
     for
     income
     taxes           154    80  (j)     224        291     93  (n)    384
                           (28) (k)
                            18  (m)
                     ---   ---          ---        ---    ---         ---

    Net
     income       $1,386  $132       $1,518     $1,121   $187      $1,308
                  ======  ====       ======     ======   ====      ======

    Earnings
     per share:
      Basic        $1.36              $1.49      $1.06              $1.24
      Diluted (o)  $1.36              $1.49 (b)  $1.05              $1.23 (b)

    Average
     shares
     used in
     calculation
     of earnings
     per share:
      Basic        1,016              1,016      1,058              1,058
      Diluted (o)  1,022              1,021 (b)  1,064              1,063 (b)


    (a) - (o)   See explanatory notes on the following pages, which includes
                a discussion in note (a) of the retrospectively applied change
                in method of accounting for our convertible notes.



    Amgen Inc.
    Condensed Consolidated Statements of Income and
    Reconciliation of GAAP Earnings to "Adjusted" Earnings
    (In millions, except per share data)
    (Unaudited)

                       Nine months ended          Nine months ended
                       September 30, 2009         September 30, 2008
                       ------------------        ---------------------
                          Adjust-                        Adjust-
                   GAAP    ments   "Adjusted"   GAAP (a)  ments  "Adjusted"
                   ----   -------   --------   --------  -------  --------


    Revenues:
      Product
       sales     $10,608    $-      $10,608    $11,013     $-     $11,013
      Other
       revenues      225     -          225        239      -         239
                     ---   ---          ---        ---    ---         ---
        Total
         revenues 10,833     -       10,833      11,252     -      11,252
                  ------   ---       ------      ------   ---      ------


      Cost of sales
       (excludes
       amortization
       of certain
       acquired
       intangible
       assets
       presented
       below)      1,553    (9) (b)   1,543       1,738    (9) (b)  1,644
                            (1) (c)                        (1) (c)
                                                          (84) (h)
      Research
       and
       development 1,973   (40) (b)   1,875       2,232   (35) (b)  2,140
                            (6) (c)                        (3) (c)
                           (52) (d)                       (53) (d)
                                                           (1) (i)
      Selling,
       general
       and
       adminis-
       trative     2,640   (39) (b)   2,578       2,678   (33) (b)  2,646
                           (23) (c)                         1  (c)
      Amortization
       of certain
       acquired
       intangible
       assets        221  (221) (e)       -         221  (221) (e)      -
      Other
       charges        63   (35) (c)       -         306   (39) (c)      -
                           (28) (f)                      (267) (f)
                     ---   ---          ---         ---   ---         ---
        Total
         operating
         expenses  6,450  (454)       5,996       7,175  (745)      6,430
                   -----  ----        -----       -----  ----       -----

    Operating
     income        4,383   454        4,837       4,077   745       4,822

      Interest
       expense,
       net           436  (186) (g)     250         419  (174) (g)    245
      Interest
       and
       other
       income,
       net           182                182         264     9  (c)    273
                     ---                ---         ---   ---         ---

    Income
     before
     income
     taxes         4,129   640        4,769       3,922   928       4,850

    Provision
     for income
     taxes           455   235  (j)     820         795   294  (n)  1,089
                            87  (k)
                            25  (l)
                            18  (m)
                     ---   ---          ---         ---   ---       -----

    Net
     income       $3,674  $275       $3,949      $3,127  $634      $3,761
                  ======  ====       ======      ======  ====      ======

    Earnings
     per
     share:
      Basic        $3.60              $3.87       $2.91             $3.50
      Diluted (o)  $3.58              $3.86 (b)   $2.90             $3.49 (b)

    Average
     shares
     used in
     calculation
     of earnings
     per share:
      Basic        1,020              1,020       1,075             1,075
      Diluted (o)  1,025              1,024 (b)   1,079             1,078 (b)


    (a) - (o)   See explanatory notes on the following pages, which includes
                a discussion in note (a) of the retrospectively applied
                change in method of accounting for our convertible notes.






    Amgen Inc.
    Notes to Reconciliation of GAAP Earnings to "Adjusted" Earnings
    (In millions, except per share data)
    (Unaudited)

     (a)   Effective January 1, 2009, we adopted a new accounting standard
           that changed the method of accounting for convertible debt that
           may be partially or wholly settled in cash, which includes our
           convertible notes. In addition, as required, we revised our
           previously reported financial statements to retrospectively
           apply this change in accounting to prior periods. Under this new
           method of accounting, the debt and equity components of our
           convertible notes are bifurcated and accounted for separately.
           The equity components of our convertible notes are included in
           Stockholders' equity in our Condensed Consolidated Balance Sheets
           with a corresponding reduction in the carrying values of our
           convertible notes as of the date of issuance or modification, as
           applicable. The reduced carrying values of our convertible notes
           are being accreted back to their principal amounts through the
           recognition of non-cash interest expense. This results in
           recognizing interest expense on these borrowings at effective
           rates approximating what we would have incurred had we issued
           nonconvertible debt with otherwise similar terms.

           In connection with applying this new accounting to prior periods,
           we recorded $59 million and $174 million of additional non-cash
           interest expense in the three and nine months ended
           September 30, 2008, respectively. As a result, our previously
           reported results of operations calculated in accordance with GAAP
           have been revised for the three and nine months ended
           September 30, 2008, as follows:

                                Three months ended
                                September 30, 2008
                                ------------------
                                     Effect of the
                                          new
                      As originally    accounting
                         reported       standard    "Revised"
                      -------------  -------------  ---------
      Operating
       income                $1,483             $-     $1,483
      Interest
       expense, net              74             59        133
      Interest and
       other income,
       net                       62              -         62
                                ---            ---         --
      Income before
       income taxes           1,471            (59)     1,412
      Provision for
       income taxes             313            (22)       291
                                ---            ---        ---
      Net income             $1,158           $(37)    $1,121
                             ======           ====     ======

      Earnings per share:
         Basic                $1.09         $(0.03)     $1.06
         Diluted              $1.09         $(0.04)     $1.05



                                 Nine months ended
                                September 30, 2008
                                ------------------
                                     Effect of the
                                          new
                      As originally    accounting
                         reported       standard    "Revised"
                      -------------  -------------  ---------
      Operating
       income                $4,077             $-     $4,077
      Interest
       expense, net             245            174        419
      Interest and
       other income,
       net                      264              -        264
                                ---            ---        ---
      Income before
       income taxes           4,096           (174)     3,922
      Provision for
       income taxes             861            (66)       795
                                ---            ---        ---
      Net income             $3,235          $(108)    $3,127
                             ======          =====     ======

      Earnings per share:
         Basic                $3.01         $(0.10)     $2.91
         Diluted              $3.00         $(0.10)     $2.90


    (b)   To exclude the impact of stock option expense. For the three and
          nine months ended September 30, 2009 and 2008, the total pre-tax
          expense for employee stock options was $29 million and $88 million,
          respectively, and $25 million and $77 million, respectively.

          "Adjusted" diluted EPS including the impact of stock option expense
          for the three and nine months ended September 30, 2009 and 2008 was
          as follows:



                              Three months ended   Nine months ended
                                 September 30,       September 30,
                                 -------------      -------------
                                  2009    2008      2009      2008
                                  ----    ----      ----      ----

    "Adjusted" diluted EPS,
     excluding stock option
     expense                      $1.49   $1.23     $3.86     $3.49
      Impact of stock option
       expense (net of tax)       (0.02)  (0.02)    (0.06)    (0.05)
                                   ----    ----      ----      ----
    "Adjusted" diluted EPS,
     including stock option
     expense                      $1.47   $1.21     $3.80     $3.44
                                  =====   =====     =====     =====


    (c)  To exclude the following (expenses)/recoveries associated with our
         restructuring plan announced in August 2007 and certain additional
         cost savings initiatives subsequently identified, as follows:

                                    Separation     Asset     Other
                                      costs (1) impairment    (2)    Total
                                  ------------- ----------  ------   -----


    Three months ended
     September 30, 2009
    ------------------------------
    Research and
     development (R&D)                    $-      $(3)        $-       $(3)
    Selling, general and
     administrative (SG&A)                 -        -         (6)       (6)
    Other charges                          3        -         (4)       (1)
                                         ---      ---        ---      ----
                                          $3      $(3)      $(10)     $(10)
                                         ===      ===       ====      ====

    Three months ended
     September 30, 2008
    ------------------------------
    Other charges                         $-      $(1)       $(7)      $(8)
    Interest and other income, net         -        -         (9)       (9)
                                         ---      ---        ---      ----
                                          $-      $(1)      $(16)     $(17)
                                         ===      ===       ====      ====

    Nine months ended
     September 30, 2009
    ------------------------------
    Cost of sales (excludes
     amortization of certain acquired
    intangible assets)                    $-      $(1)        $-       $(1)
    R&D                                    3       (8)        (1)       (6)
    SG&A                                   2        -        (25)      (23)
    Other charges                        (31)       -         (4)      (35)
                                         ---      ---        ---      ----
                                        $(26)     $(9)      $(30)     $(65)
                                         ===      ===       ====      ====

    Nine months ended
     September 30, 2008
    ------------------------------
    Cost of sales (excludes
     amortization of certain acquired
     intangible assets)                   $-      $(1)        $-       $(1)
    R&D                                   (3)       -          -        (3)
    SG&A                                   -        -          1         1
    Other charges                         (4)     (15)       (20)      (39)
    Interest and other income, net         -        -         (9)       (9)
                                         ---      ---        ---      ----
                                         $(7)    $(16)      $(28)     $(51)
                                         ===      ===       ====      ====

        (1)  Severance and other separation costs partially offset in 2009
             by the reversal of previously accrued expenses for bonuses and
             stock-based compensation awards, which will be forfeited as a
             result of the employees' termination.
        (2)  To exclude (i) from SG&A in 2009, integration costs associated
             with certain cost saving initiatives, (ii) from Other charges
             in 2009  and 2008, loss accruals for leases principally related
             to certain facilities that will not be used in our business and
             (iii) from Interest and  other income, net in 2008, loss accrual
             on the sale of certain less significant marketed products and
             related assets.

    (d)  To exclude the ongoing, non-cash amortization of the R&D technology
         intangible assets acquired with the acquisitions of Abgenix, Inc.
         ("Abgenix") and Avidia, Inc. ("Avidia").

    (e)  To exclude the ongoing, non-cash amortization of acquired product
         technology rights, primarily ENBREL, related to the Immunex
         Corporation ("Immunex") acquisition.

    (f)  To exclude loss accruals for settlements of certain commercial
         legal proceedings.

    (g)  To exclude the incremental non-cash interest expense resulting
         from our adoption of a new accounting standard for our convertible
         notes (see (a) above).

    (h)  To exclude the write-off of inventory resulting from a strategic
         decision to change manufacturing processes.

    (i)  To exclude merger related expenses incurred due to the Alantos
         Pharmaceutical Holding, Inc. acquisition, primarily related to
         incremental costs associated with retention.

    (j)  To reflect the tax effect of the above adjustments for 2009,
         excluding certain of the loss accruals for settlements of commercial
         legal proceedings (see (f) above).

    (k)  To exclude the income tax benefit (expense) recognized as the
         result of resolving certain non-routine transfer pricing issues
         with the Internal  Revenue Service ("IRS") for prior periods.

    (l)  To exclude the net tax benefit resulting from adjustments to
         previously established deferred taxes, primarily related to prior
         acquisitions and  stock option expense, due to changes in California
         tax law effective for future periods.

    (m)  To exclude the tax benefit principally related to certain prior
         period charges excluded from "Adjusted" earnings.

    (n)  To reflect the tax effect of the above adjustments for 2008,
         excluding (i) certain of the restructuring charges (see (c) above),
         (ii) certain of the  loss accruals for settlements of commercial
         legal proceedings (see (f) above) and (iii) certain components of
         the write-off of inventory (see (h) above).

    (o)  The following table presents the computations for GAAP and
         "Adjusted" diluted earnings per share, computed under the treasury
         stock  method. "Adjusted" earnings per share presented below
         excludes stock option expense:


                              Three months ended     Three months ended
                              September 30, 2009     September 30, 2008
                              ------------------     ------------------
                              GAAP  "Adjusted"        GAAP  "Adjusted"
                              ----  ------------      ----  -----------
      Income (Numerator):
        Net income for basic
         and diluted EPS     $1,386       $1,518     $1,121      $1,308
                             ======       ======     ======      ======

      Shares (Denominator):
        Weighted-average
         shares for basic
         EPS                  1,016        1,016      1,058       1,058
        Effect of
         dilutive
         securities               6            5 (*)      6           5 (*)
                                ---          ---        ---         ---
        Weighted-average
         shares for diluted
         EPS                  1,022        1,021      1,064       1,063
                              =====        =====      =====       =====

      Diluted
       earnings per
       share                  $1.36        $1.49      $1.05       $1.23
                              =====        =====      =====       =====


                              Nine months ended       Nine months ended
                              September 30, 2009     September 30, 2008
                              ------------------     ------------------
                              GAAP   "Adjusted"       GAAP  "Adjusted"
                              ----   -----------      ----  -----------
      Income (Numerator):
        Net income for basic
         and diluted EPS     $3,674       $3,949     $3,127      $3,761
                             ======       ======     ======      ======

      Shares (Denominator):
        Weighted-average
         shares for basic
         EPS                  1,020        1,020      1,075       1,075
        Effect of
         dilutive
         securities               5            4 (*)      4           3 (*)
                                ---          ---        ---         ---
        Weighted-average
         shares for diluted
         EPS                  1,025        1,024      1,079       1,078
                              =====        =====      =====       =====

      Diluted
       earnings per
       share                  $3.58        $3.86      $2.90       $3.49
                              =====        =====      =====       =====

    (*)  Dilutive securities used to compute "Adjusted" diluted earnings
         per share for the three and nine months ended September 30, 2009
         and 2008 were computed under the treasury stock method assuming
         that we do not expense stock options.



    Amgen Inc.
    Product Sales Detail by Product and Geographic Region
    (In millions)
    (Unaudited)


                                       Three months   Nine months
                                          ended          ended
                                       September 30,   September 30,
                                      --------------  --------------
                                        2009   2008    2009    2008
                                        ----   ----    ----    ----

    Aranesp(R) - U.S.                   $333   $458    $963  $1,290

    Aranesp(R) - International           352    387   1,041   1,141

    EPOGEN(R) - U.S.                     663    634   1,866   1,810

    Neulasta(R) - U.S.                   657    633   1,876   1,850

    NEUPOGEN(R) - U.S.                   240    223     672     667

    Neulasta(R) - International          214    219     603     620

    NEUPOGEN(R) - International           99    117     290     342

    Enbrel(R) - U.S.                     872    838   2,430   2,531

    Enbrel(R) - International             52     55     151     154

    Sensipar(R) - U.S.                   108    111     320     306

    Sensipar(R) - International           57     50     160     138

    Vectibix(R) - U.S.                    23     26      72      83

    Vectibix(R) - International           35     15      95      24

    Other product sales - U.S.            22      6      54      23

    Other product sales - International    9     12      15      34
                                         ---    ---     ---     ---

      Total product sales             $3,736 $3,784 $10,608 $11,013
                                      ====== ====== ======= =======


    U.S.                              $2,918 $2,929  $8,253  $8,560

    International                        818    855   2,355   2,453
                                         ---    ---   -----   -----

      Total product sales             $3,736 $3,784 $10,608 $11,013
                                      ====== ====== ======= =======



    Amgen Inc.
    Condensed Consolidated Balance Sheets - GAAP
    (In millions)
    (Unaudited)

                                           September 30,  December 31,
                                                2009        2008 (a)
                                                ----        --------
    Assets
    Current assets:
      Cash, cash equivalents and
       marketable securities                   $14,013       $9,552
      Trade receivables, net                     2,331        2,073
      Inventories                                2,155        2,075
      Other current assets                       1,475        1,521
                                                 -----        -----
          Total current assets                  19,974       15,221
    Property, plant and
     equipment, net                              5,743        5,879
    Intangible assets, net                       2,674        2,988
    Goodwill                                    11,335       11,339
    Other assets                                 1,214        1,000
                                                 -----        -----
          Total assets                         $40,940      $36,427
                                               =======      =======

    Liabilities and
     Stockholders' Equity
    Current liabilities:
      Accounts payable and accrued
       liabilities                              $3,903       $3,886
      Current portion of other long-
       term debt                                 1,000        1,000
                                                 -----        -----
          Total current liabilities              4,903        4,886
    Convertible notes                            4,447        4,257
    Other long-term debt                         6,089        4,095
    Other non-current
     liabilities                                 2,643        2,304
    Stockholders' equity                        22,858       20,885
                                                ------       ------
          Total liabilities and
           stockholders' equity                $40,940      $36,427
                                               =======      =======

    Shares outstanding                           1,016        1,047

    (a)  As discussed in more detail above in the notes to the Reconciliation
         of GAAP Earnings to "Adjusted" Earnings, effective January 1, 2009,
         we adopted a new accounting standard, which changed the method of
         accounting for our convertible notes. In addition, as required, we
         revised our previously reported financial statements to
         retrospectively apply this change in accounting to prior periods.
         As a result, our previously reported Consolidated Balance Sheet as
         of December 31, 2008 has been revised as follows:



                                               December 31, 2008
                                               -----------------
                             As originally    Effect of the new
                                reported      accounting standard  "Revised"
                             -------------    -------------------  ---------
        Other non-current
         assets                 $1,016               $(16)          $1,000
        Convertible notes        5,081               (824)(1)        4,257
        Other non-current
         liabilities             1,995                309 (2)        2,304
        Stockholders' equity     20,386               499 (3)       20,885


      (1)  The reduction in Convertible notes reflects the bifurcation of
           the equity components of our convertible notes partially offset
           by the accretion of the reduced carrying values resulting from
           the recognition of non-cash interest expense through
           December 31, 2008.

      (2)  The increase in Other non-current liabilities reflects the
           impact of deferred income taxes.

      (3)  The increase in Stockholders' equity reflects the addition of
           the equity components of our convertible notes, partially
           offset by (i) non-cash interest expense recognized through
           December 31, 2008 related to the accretion of the reduced
           carrying values of our convertible notes and (ii) the impact
           of deferred income taxes.



    Amgen Inc.
    Reconciliation of GAAP Debt Outstanding to "Adjusted" Debt
     Outstanding
    (In billions)
    (Unaudited)


                                            September 30, 2009
                                            ------------------
                                           Adjustments for the
                                              new accounting
                                  GAAP           standard      "Adjusted"
                                  ----     ------------------- ----------

      Total debt outstanding     $11.5           $0.7 (a)         $12.2

    (a)  To exclude the impact of the adoption of a new accounting standard
         which changed the method of accounting for our convertible notes,
         as discussed on the preceding pages.



    Amgen Inc.
    Reconciliation of GAAP Earnings Per Share
     Guidance to "Adjusted" Earnings Per Share
     Guidance for the Year Ending December 31, 2009
    (Unaudited)
                                                                    2009
                                                                    ----

    GAAP earnings per share guidance                       $4.51 - $4.68

    Known adjustments to arrive at "Adjusted" earnings:
      Amortization of acquired intangible assets,
       product technology rights                      (a)           0.18
      Incremental non-cash interest expense           (b)           0.15
      Tax settlement                                  (c)          (0.08)
      Stock option expense                            (d)   0.06 -  0.08
      Cost savings initiatives                        (e)           0.04
      Amortization of acquired intangible assets,
       R&D technology rights                          (f)           0.04
      Legal settlements                               (g)           0.02
      California tax law change                       (h)          (0.02)
      Tax benefit for prior period charges            (i)          (0.02)
                                                                   -----

    "Adjusted" earnings per share guidance                 $4.90 - $5.05
                                                           =====   =====

    (a)  To exclude the ongoing, non-cash amortization of acquired product
         technology rights, primarily ENBREL, related to the Immunex
         acquisition.

    (b)  To exclude the incremental non-cash interest expense resulting from
         our adoption of a new accounting standard.

    (c)  To exclude the income tax benefit, net recognized as the result of
         resolving certain non-routine transfer pricing issues with the IRS
         for prior periods.

    (d)  To exclude stock option expense.

    (e)  To exclude expense related to cost saving initiatives.

    (f)  To exclude the ongoing, non-cash amortization of the R&D technology
         intangible assets acquired with the Abgenix and Avidia acquisitions.

    (g)  To exclude loss accruals for settlements of certain commercial
         legal proceedings.

    (h)  To exclude the net tax benefit resulting from adjustments to
         previously established deferred taxes, primarily related to prior
         acquisitions and stock option expense, due to changes in California
         tax law effective for future periods.

    (i)  To exclude the tax benefit principally related to certain prior
         period charges excluded from "Adjusted" earnings.



    CONTACT:  Amgen, Thousand Oaks
    David Polk, 805-447-4613 (media)
    Arvind Sood, 805-447-1060 (investors)

(Logo: http://www.newscom.com/cgi-bin/prnh/20081015/AMGENLOGO)

SOURCE Amgen